Showing 6971-6980 of 7723 results for "".
- Five-Year Data Show Sustained Efficacy, Safety for Cosentyxhttps://practicaldermatology.com/news/five-year-data-show-sustained-efficacy-safety-for-cosentyx/2458054/Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase III data. These data were presented for
- Two Galderma Rosacea Therapies Work Well Togetherhttps://practicaldermatology.com/news/two-galderma-rosacea-therapies-work-well-together/2458061/Combined use of Galderma’s SOOLANTRA (ivermectin1% Cream) and Mirvaso (Brimonidine 0.33% Gel) pack a one-two punch against the erythema and inflammatory lesions of rosacea, the MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCe
- Dermira Presents New Data on Late-Stage Programs at European Dermatology Congresshttps://practicaldermatology.com/news/dermira-presents-new-data-on-late-stage-programs-at-european-dermatology-congress/2458066/Dermira, Inc. will present data from its glycopyrronium tosylate (formerly DRM04) and Cimzia (certolizumab pegol) Phase 3 clinical programs in poster sessions at the 26th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Geneva, Switzerland, September 13&
- GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologicshttps://practicaldermatology.com/news/gbi-research-global-dermatology-pipeline-to-see-shift-toward-increased-use-of-biologics/2458071/The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of the pipeline dominated by generics and biosimilars, according to GBI Research. The company
- FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseaseshttps://practicaldermatology.com/news/fda-greenlights-humira-biosim-cyltezo-for-multiple-inflammatory-diseases/2458073/The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including:
- Psoriasis Severity Linked to Increased Risk of Deathhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-increased-risk-of-death/2458074/The more surface area of the body covered by psoriasis, the greater the risk of death, according to a new analysis by researchers at the Perelman School of Medicine at the University of Pennsylvania. In fact, patients with psoriasis on 10 perce
- Record Growth Noted for PCA SKINhttps://practicaldermatology.com/news/record-growth-noted-for-pca-skin/2458076/PCA SKIN® ranked as the #2 fastest growing professional skincare brand in 2017, according to the global market research and management consulting firm, Kline. Kline Company lists PCA SKIN as hav
- The Prescription Dermatological Drugs Market Forecasthttps://practicaldermatology.com/news/the-prescription-dermatological-drugs-market-forecast/2458079/The "World Prescription Dermatological Drugs Market, 10th Edition" report, now available from Research and Markets shows the field
- Bioré Skincare Partners with Girl Uphttps://practicaldermatology.com/news/bior-skincare-partners-with-girl-up/2458081/To celebrate the launch of their new Limited Edition Deep Cleansing Pore Strips, Bioré® Skincare is partnering with Girl Up™, a United Nations Foundation campaign. Girl Up mobilizes girls and women across the globe to raise awareness and funds for United Nations prog
- Power Couple: Stroll Health Teams Up With First Dermhttps://practicaldermatology.com/news/power-couple-stoll-health-teams-up-with-first-derm/2458085/Stroll Health and First Derm are partnering to make dermatology care more accessible and available at a fair price. Stroll's health care